In 2020, COVID-19 and the associated lockdowns had a huge impact on how clinical trials were being run across the world. One result of that was a rapid increase in the adoption of decentralized or hybrid trials. Indeed, our recent study showed that 79% of the industry said COVID-19 has increased their use of decentralized or hybrid trials, and 84% say it is 'likely' or 'certain' that their company will increase adoption in the next two years. The impact of the pandemic on clinical trials worldwide has offered an unparalleled opportunity for industry defining change.
In this edition of the Clinical Trials eBook Series, we explore the rapidly increasing adoption of decentralized clinical trials, the challenges that still need to be overcome and how it provides a chance for faster studies with better data and a very real improvement in patient-centricity.
Explore or download the interactive eBook by clicking on the image above or here.
Features in the eBook include:
- Implementing decentralized/hybrid clinical trials through interaction between all stakeholders: A video panel of leading industry experts, led by Maria Kuthning, discussing the interaction between all stakeholders on decentralized trails, followed by a Q&A with the audience.
- How the Decentralized Trials and Research Alliance is using collaboration to increase adoption of decentralized clinical trials: An interview with Craig Lipset to discuss the associations and more broadly the implementation of decentralized and hybrid trials during COVID-19 and beyond.
- 5 ways to make patients stakeholders in clinical trials today: Megan Liles discusses patient-centricity, the progress we have made but how we need to do more going forward into a post-COVID era.
- Your Questions Answered: Practical use cases for digital measures: biomarkers, trial endpoints and remote monitoring solution: Kai Langel, Director of Clinical Innovation at Janssen, answers your questions on digital measurements.